Mabwell Bioscience Receives FDA Green Light for B7-H3 Targeting ADC 7MW3711
Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a biopharmaceutical company based in China, has announced...
Company
BMS and Sichuan Biokin Commence Joint Development of EGFR/HER3-Targeted ADC
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a Chinese pharmaceutical company, has announced that a...
Everest Medicines Terminates Agreement with Providence Therapeutics, Retains mRNA Rights
Everest Medicines (HKG: 1952), a biopharmaceutical company based in China, has announced the termination of...
Jacobio Pharma Gets CDE Green Light for Phase III Study Combining Gleevec Inhibitors in NSCLC
Jacobio Pharma (HKG: 1167), a China-based pharmaceutical company, has announced that it has received approval...
Neurophth Biotechnology Completes Enrollment and Dosing in US Clinical Study for ND4-LHON Gene Therapy
Neurophth Biotechnology Ltd, a leading gene therapy specialist based in China, has announced the completion...
Biocytogen Pharmaceuticals Inks Antibody Evaluation Deal with Gilead Sciences
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315), a China-based biopharmaceutical company, has announced an antibody...
Evopoint Biosciences Secures USD 97.2 Million in Series E Financing to Boost Clinical Trials and Commercialization
Evopoint Biosciences Co., Ltd., a Suzhou-based biopharmaceutical company, has announced the successful completion of a...
Phanes Therapeutics’ PT886 Receives CDE Approval for Clinical Trials in Advanced Solid Tumors
Sino-US biotechnology company Phanes Therapeutics Inc. has announced that it has received clinical trial approval...
ImmunoTech Biopharm Gets NMPA Green Light for Clinical Study of aT19 Injection for B-ALL
ImmunoTech Biopharm Ltd (HKG: 6978), a specialist in chimeric antigen receptor T-cell (CAR-T) therapies based...
AstraZeneca’s Tagrisso Wins Expanded FDA Approval for EGFR-mutated NSCLC
UK pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) has received a new indication approval from the...
Innovent Biologics’ IBI311 Achieves Primary Endpoint in Phase III Study for Thyroid Eye Disease
Innovent Biologics Inc., (HKG: 1801), a biopharmaceutical company based in China, has announced that its...
GSK and Peers Respond to FTC Criticism, Withdraw Patent Listings from US Orange Book
Three pharmaceutical companies, including the UK’s GSK (NYSE: GSK), have responded to the Federal Trade...
Astellas Pharma Partners with Kelonia Therapeutics to Advance CAR-T Cell Therapies
Astellas Pharma Inc. (TYO: 4503) has announced a strategic research collaboration and licensing agreement with...
Denali Therapeutics Faces Setback as ALS Trial Fails to Meet Primary Endpoint
Denali Therapeutics (NASDAQ: DNLI) has announced disappointing results from a Phase II trial of its...
Hainan Poly Pharm Wins FDA Nod for Generic Version of UCB’s Vimpat
Hainan Poly Pharm Co., Ltd (SHE: 300630), a Chinese pharmaceutical company, has announced that it...
US Lawmakers Call for Sanctions Against WuXi AppTec and WuXi Biologics Over National Security Concerns
US politicians have intensified their opposition to China’s biotech industry, with Congressmen and Senators sending...
Novartis Begins Review of 70% Stake in Indian Unit, Strategic Options Under Consideration
Novartis (NYSE: NVS) has initiated a review process concerning its 70.68% stake in Novartis India...
Boao Yiling Life Care Center Launches Innovative Dental Technologies Under Pilot Medical Policy
Boao Yiling Life Care Center has successfully completed the inaugural use of a dental comprehensive...
Brii Biosciences Acquires VBI Vaccines’ Intellectual Property and Manufacturing Rights in Strategic Deal
Brii Biosciences Ltd (HKG: 2137), based in China, has reached an agreement with US-based VBI...
LianBio to Wind Down Operations Amid Market Challenges, Announces Special Dividend
LianBio (OTCMKTS: LIANY), one of China’s prominent biotechnology firms, has announced plans to wind down...